Latham & Watkins Advises Placement Agents in PIPE in Connection with Roivant Sciences and Montes Archimedes Acquisition Corp. Combination

Bicoastal capital markets team advised on the transaction.

May 04, 2021

Roivant Sciences, a biopharmaceutical and healthcare technology company, and Montes Archimedes Acquisition Corp. (Nasdaq: MAAC), a special purpose acquisition company sponsored by Patient Square Capital, have announced that they have entered into a definitive business combination agreement. Upon closing of the transaction, outstanding shares and warrants of MAAC will be exchanged for newly issued shares and warrants of Roivant Sciences, which is expected to be listed on Nasdaq under the new ticker symbol "ROIV." 

The transaction is expected to deliver up to US$611 million of gross proceeds to fund discovery and development programs. This includes up to US$411 million currently held in MAAC's trust account, as well as a concurrent US$200 million common stock private investment in public equity (PIPE) priced at US$10 per share. New institutional and strategic investors and existing Roivant shareholders have committed to participate in the PIPE, including Fidelity Management & Research Company LLC, Eventide Asset Management, Suvretta Capital, Palantir Technologies, RTW Investments, LP, Viking Global Investors, Sumitomo Dainippon Pharma, and SB Management, a subsidiary of SoftBank Group Corp. Proceeds are expected to extend the company's operating runway through mid-2024.

Latham & Watkins LLP represented the placement agents in connection with the PIPE with a capital markets team led by New York partner Nathan Ajiashvili, Orange County partner Shayne Kennedy, and New York partner Alison Haggerty, with New York associates Salvatore Vanchieri, Andrew Weitzel, and Ian Lachow.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.